Beam Therapeutics Inc

NASDAQ:BEAM   4:00:00 PM EDT
33.04
-0.92 (-2.71%)
7:50:57 PM EDT: $33.90 +0.86 (+2.60%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.70B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.42 Million
Adjusted EPS-$1.41
See more estimates
10-Day MA$34.22
50-Day MA$32.23
200-Day MA$27.90
See more pivots

Beam Therapeutics Inc Stock, NASDAQ:BEAM

238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016
United States of America
Phone: +1.857.327.8775
Number of Employees: 436

Description

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.